AU2015316799B2 - Macrocyclic RIP2 kinase inhibitors - Google Patents
Macrocyclic RIP2 kinase inhibitors Download PDFInfo
- Publication number
- AU2015316799B2 AU2015316799B2 AU2015316799A AU2015316799A AU2015316799B2 AU 2015316799 B2 AU2015316799 B2 AU 2015316799B2 AU 2015316799 A AU2015316799 A AU 2015316799A AU 2015316799 A AU2015316799 A AU 2015316799A AU 2015316799 B2 AU2015316799 B2 AU 2015316799B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- halo
- het
- optionally
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Fc1cc(OCCN(CCCC2)C2*CNc2nc3c-4cn[n]3cc2)cc-4c1 Chemical compound Fc1cc(OCCN(CCCC2)C2*CNc2nc3c-4cn[n]3cc2)cc-4c1 0.000 description 4
- RPIKHRLOOAVQRY-UHFFFAOYSA-N C(C1)CN(CCO2)C1CNc(cc[n]1nc3)nc1c3-c1cccc2c1 Chemical compound C(C1)CN(CCO2)C1CNc(cc[n]1nc3)nc1c3-c1cccc2c1 RPIKHRLOOAVQRY-UHFFFAOYSA-N 0.000 description 1
- QCPPNQBVOQVJTE-UHFFFAOYSA-N CN(CC(CCC1)N1CCO1)c(cc[n]2nc3)nc2c3-c2cccc1c2 Chemical compound CN(CC(CCC1)N1CCO1)c(cc[n]2nc3)nc2c3-c2cccc1c2 QCPPNQBVOQVJTE-UHFFFAOYSA-N 0.000 description 1
- MENPYAFXUZUAKV-MRXNPFEDSA-N Clc1cc(OCCCN(CCC2)[C@H]2CNc2nc3c-4cn[n]3cc2)cc-4c1 Chemical compound Clc1cc(OCCCN(CCC2)[C@H]2CNc2nc3c-4cn[n]3cc2)cc-4c1 MENPYAFXUZUAKV-MRXNPFEDSA-N 0.000 description 1
- ASSLKTYURCITCF-HNNXBMFYSA-N Clc1cc(OCCN(CCC2)[C@@H]2CNc2nc3c-4cn[n]3cc2)cc-4c1 Chemical compound Clc1cc(OCCN(CCC2)[C@@H]2CNc2nc3c-4cn[n]3cc2)cc-4c1 ASSLKTYURCITCF-HNNXBMFYSA-N 0.000 description 1
- KLHLBYYXDWZTGO-INIZCTEOSA-N Fc1cc(OCCCN(CCC2)[C@@H]2CNc2nc3c-4cn[n]3cc2)cc-4c1 Chemical compound Fc1cc(OCCCN(CCC2)[C@@H]2CNc2nc3c-4cn[n]3cc2)cc-4c1 KLHLBYYXDWZTGO-INIZCTEOSA-N 0.000 description 1
- NWIWCNPHEKBKHL-HNNXBMFYSA-N Fc1cc(OCCN(CCC2)[C@@H]2CNc2nc3c-4cn[n]3cc2)cc-4c1 Chemical compound Fc1cc(OCCN(CCC2)[C@@H]2CNc2nc3c-4cn[n]3cc2)cc-4c1 NWIWCNPHEKBKHL-HNNXBMFYSA-N 0.000 description 1
- LIOJBIZDAHGEGF-UHFFFAOYSA-N O=S(C1)(CC1(CC[N-]1)CC1I)=O Chemical compound O=S(C1)(CC1(CC[N-]1)CC1I)=O LIOJBIZDAHGEGF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185130.3 | 2014-09-17 | ||
| EP14185130 | 2014-09-17 | ||
| PCT/EP2015/071347 WO2016042087A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic rip2 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015316799A1 AU2015316799A1 (en) | 2017-04-27 |
| AU2015316799B2 true AU2015316799B2 (en) | 2019-07-11 |
Family
ID=51687776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015316799A Active AU2015316799B2 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic RIP2 kinase inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10676486B2 (enExample) |
| EP (1) | EP3194407B1 (enExample) |
| JP (1) | JP6736545B2 (enExample) |
| KR (1) | KR102563829B1 (enExample) |
| CN (1) | CN106687464B (enExample) |
| AU (1) | AU2015316799B2 (enExample) |
| BR (1) | BR112017004035B1 (enExample) |
| CA (1) | CA2958782C (enExample) |
| DK (1) | DK3194407T3 (enExample) |
| EA (1) | EA032872B1 (enExample) |
| ES (1) | ES2763344T3 (enExample) |
| HR (1) | HRP20192334T1 (enExample) |
| HU (1) | HUE048518T2 (enExample) |
| IL (1) | IL250544B (enExample) |
| LT (1) | LT3194407T (enExample) |
| MX (1) | MX376087B (enExample) |
| MY (1) | MY186523A (enExample) |
| PL (1) | PL3194407T3 (enExample) |
| PT (1) | PT3194407T (enExample) |
| SA (1) | SA517381087B1 (enExample) |
| SG (1) | SG11201701116XA (enExample) |
| SI (1) | SI3194407T1 (enExample) |
| TW (1) | TWI709563B (enExample) |
| UA (1) | UA121315C2 (enExample) |
| WO (1) | WO2016042087A1 (enExample) |
| ZA (1) | ZA201701331B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| CA3168814A1 (en) | 2020-01-31 | 2021-08-05 | Oncodesign S.A. | Macrocyclic rip2-kinase inhibitors |
| AU2023339247A1 (en) * | 2022-09-07 | 2025-03-27 | Suzhou Langrui Biopharmaceutical Co., Ltd. | Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof |
| WO2024146541A1 (en) * | 2023-01-03 | 2024-07-11 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Macrocyclic compounds as usp1 inhibitors |
| WO2025212514A2 (en) * | 2024-04-02 | 2025-10-09 | Interline Therapeutics, Inc. | Methods of treating inflammatory diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102596957A (zh) * | 2009-07-09 | 2012-07-18 | 阵列生物制药公司 | 作为TRK激酶抑制剂的被取代的吡唑并[1,5-a]嘧啶化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| ES2166786T3 (es) | 1993-10-01 | 2002-05-01 | Astrazeneca Ab | Procedimiento i. |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US7750007B2 (en) * | 2006-11-06 | 2010-07-06 | Supergen, Inc. | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| MX347765B (es) | 2011-09-30 | 2017-05-12 | Oncodesign Sa | Inhibidores macrociclicos de la quinasa flt3. |
| PT2760453T (pt) | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
-
2015
- 2015-09-17 AU AU2015316799A patent/AU2015316799B2/en active Active
- 2015-09-17 US US15/505,976 patent/US10676486B2/en active Active
- 2015-09-17 EP EP15766800.5A patent/EP3194407B1/en active Active
- 2015-09-17 ES ES15766800T patent/ES2763344T3/es active Active
- 2015-09-17 SG SG11201701116XA patent/SG11201701116XA/en unknown
- 2015-09-17 HR HRP20192334TT patent/HRP20192334T1/hr unknown
- 2015-09-17 PL PL15766800T patent/PL3194407T3/pl unknown
- 2015-09-17 UA UAA201703558A patent/UA121315C2/uk unknown
- 2015-09-17 MX MX2017003469A patent/MX376087B/es active IP Right Grant
- 2015-09-17 JP JP2017514486A patent/JP6736545B2/ja active Active
- 2015-09-17 CA CA2958782A patent/CA2958782C/en active Active
- 2015-09-17 KR KR1020177010128A patent/KR102563829B1/ko active Active
- 2015-09-17 MY MYPI2017700447A patent/MY186523A/en unknown
- 2015-09-17 DK DK15766800.5T patent/DK3194407T3/da active
- 2015-09-17 LT LTEP15766800.5T patent/LT3194407T/lt unknown
- 2015-09-17 EA EA201790609A patent/EA032872B1/ru unknown
- 2015-09-17 PT PT157668005T patent/PT3194407T/pt unknown
- 2015-09-17 TW TW104130751A patent/TWI709563B/zh active
- 2015-09-17 WO PCT/EP2015/071347 patent/WO2016042087A1/en not_active Ceased
- 2015-09-17 BR BR112017004035-2A patent/BR112017004035B1/pt active IP Right Grant
- 2015-09-17 HU HUE15766800A patent/HUE048518T2/hu unknown
- 2015-09-17 SI SI201531050T patent/SI3194407T1/sl unknown
- 2015-09-17 CN CN201580050163.3A patent/CN106687464B/zh active Active
-
2017
- 2017-02-09 IL IL250544A patent/IL250544B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01331A patent/ZA201701331B/en unknown
- 2017-03-14 SA SA517381087A patent/SA517381087B1/ar unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102596957A (zh) * | 2009-07-09 | 2012-07-18 | 阵列生物制药公司 | 作为TRK激酶抑制剂的被取代的吡唑并[1,5-a]嘧啶化合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012314376B2 (en) | Macrocyclic FLT3 kinase inhibitors | |
| JP5658662B2 (ja) | ヒスタミンｈ４受容体のジアミノピリジン、ピリミジン、及びピリダジンモジュレーター | |
| DK2970333T3 (en) | MACROCYCLIC LRRK2 KINase INHIBITORS | |
| AU2015316801B2 (en) | Macrocyclic LRRK2 kinase inhibitors | |
| WO2014140299A1 (en) | Macrocyclic rip2 kinase inhibitors | |
| WO2024032689A1 (zh) | 基于异吲哚啉取代戊二酰亚胺骨架的化合物及其应用 | |
| WO2014140313A1 (en) | Macrocyclic salt-inducible kinase inhibitors | |
| EP3194407B1 (en) | Macrocyclic rip2 kinase inhibitors | |
| JP2017503838A (ja) | ６−フェニル−または６−（ピリジン−３−イル）インダゾール誘導体および使用方法 | |
| JP2024539633A (ja) | 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用 | |
| TW202535869A (zh) | 一種含有噻唑基的哌啶并嘧啶類衍生物、其製備方法及其醫藥上的應用 | |
| HK1232862A1 (en) | Macrocyclic rip2 kinase inhibitors | |
| NZ730758B2 (en) | Macrocyclic rip2 kinase inhibitors | |
| EP2968325A1 (en) | Macrocyclic rip2 kinase inhibitors | |
| HK1232862B (zh) | 大环rip2激酶抑制剂 | |
| WO2026107076A1 (en) | Cdk2 inhibitor compounds | |
| EP2968326A1 (en) | Macrocyclic salt-inducible kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: ONCODESIGN PRECISION MEDICINE (OPM) Free format text: FORMER OWNER(S): ONCODESIGN S.A. |